Substrates of human cytochromes P450 from families CYP1 and CYP2: Analysis of enzyme selectivity and metabolism

Drug Metabolism and Drug Interactions

Volumn 20, Issue 3, 2004, Pages 111-142

  Lewis, David F V ^a   Lake, Brian G ^a,b   Dickins, Maurice ^c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b BIBRA INTERNATIONAL   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Cytochrome P450; Drug metabolism; Structure activity relationships

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; 4 BIPHENYLAMINE; 4 NITROANISOLE; AFLATOXIN; CAFFEINE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 1A2; CYTOCHROME P450 2A; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; ESTRADIOL; ETHOXYRESORUFIN; HYDROGEN; LOSIGAMONE; MELATONIN; NAPROXEN; NICOTINE; PHENACETIN; PROPRANOLOL; RESORUFIN; TACRINE; THEOPHYLLINE; UNINDEXED DRUG;

ARTICLE; DATA BASE; DEMETHYLATION; ENZYME METABOLISM; ENZYME STRUCTURE; ENZYME SUBSTRATE; EPOXIDATION; HUMAN; HYDROGEN BOND; HYDROXYLATION;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; DATABASES, FACTUAL; HUMANS; HYDROGEN BONDING; MIXED FUNCTION OXYGENASES; MODELS, CHEMICAL; OXIDOREDUCTASES, N-DEMETHYLATING; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 6344231985     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. nd Ed. New York: Plenum, 1995.
2. Lewis DFV. Cytochromes P450: Structure, Function and Mechanism. London: Taylor & Francis, 1996.
3. Lewis DFV. Guide to Cytochromes P450 Structure and Function. London: Taylor & Francis, 2001.
4. Nelson DR. Introductory remarks on human CYPs. Drug Metab Rev 2002; 34: 1-5.
5. Guengerich FJ. Update information on human P450s. Drug Metab Rev 2002; 34: 7-15.
6. nd Ed. Edinburgh: Churchill-Livingstone, 1999.
7. Rendic S, DiCarlo FJ. Human cytochrome P450 enzyme: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997; 29: 413-580.
8. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448.
9. Lewis DFV. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 2003; 10: 1955-1972.
10. Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 1999; 47: 625-635.
11. Tucker GT, Houston JB, Huang S-M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 2001; 52: 107-117.
12. Lu AYH, Wang RW, Lin JH. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 2003; 31: 345-350.
13. Pelkonen O, Maenpaa J, Taavitsainen P, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998; 28: 1203-1253.
14. Lewis DFV, Modi S, Dickins M. Structure-activity relationships for human cytochrome P450 substrates and inhibitors. Drug Metab Rev 2002; 34: 69-82.
15. Mansch C, Leo AJ. Substituent Constants for Correlation Analysis in Chemistry and Biology. New York: Wiley, 1979.
16. Mansch C, Leo A, Hoekman D. Exploring QSAR: Hydrophobic, Electronic and Steric Constants. Washington, DC: American Chemical Society, 1995.
17. Newton DW, Kluza RB. pKa values of medicinal compounds in pharmacy practice. Drug Intell Clin Pharm 1978; 12: 546-554.
18. Sangster J. Octanol-water partition coefficients of simple organic compounds. J Phys Chem Ref Data 1989; 18: 1111-1229.
19. Suzuki T, Kudo Y. Automatic log P estimation based on combined additive modeling methods. J Comput Aid Mol Design 1990; 4: 155-198.
20. Elks J, Ganellin CR. Dictionary of Drugs. London: Chapman and Hall, 1990.
21. ‡ values-possible implications in chemotherapy and biotechnology. Biochem Pharmacol 2001; 61: 1049-1055.
22. m and V/K in enzyme kinetics, Journal of Chem Educ 1998; 75: 1153-1157.
23. Lewis DFV. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys 2003; 409: 32-46.
24. Guengerich FP, Hanna IH, Martin MV, Gillam EMJ. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry 2003; 42: 1245-1253.
25. Lewis DFV. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002; 32: 305-323.
26. Lewis DFV, Lake BG, Dickins M, Goldfarb PS. Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactions. Drug Metab Drug Interact 2003; 19: 115-135.
27. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 2089-2098.
28. Williams PA, Cosme J, Ward A, Angove HC, Vinkovic DM, Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424: 464-468.
29. Lewis DFV. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004; 5: 305-318.
30. Lewis DFV, Lake BG, Bird MG, Loizou GD, Dickins M, Goldfarb PS. Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme-substrate and enzyme-inhibitor interactions. Toxicol Vitro 2003; 17: 93-105.
31. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, Miners JO. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994; 47: 1767-1776.
32. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, Miners JO. Caffeine as a probe for human cytochrome P450: validation using cDNA expression, immuno-inhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992; 2: 173-183.
33. Zhao K, Murray S, Davies DS, Boobis AR, Gooderham NJ. Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine (PhlP) by human liver microsomes. Carcinogenesis 1994; 15: 1285-1288.
34. Turesky RJ, Constable A, Richoz J, Varga N, Markovic J, Martin MV, Guengerich FP. Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P4501A2. Chem Res Toxicol 1998; 11: 925-936.
35. Parikh A, Josephy PD, Guengerich FP. Selection and characterization of human cytochrome P4501A2 mutants with altered catalytic properties. Biochemistry 1999; 38: 5283-5289.
36. Mammons GJ, Milton D, Stepps K, Guengerich FP, Tukey RH, Kadlubar FF. Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis 1997; 18: 851-854.
37. 1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P4501A2 and 3A4. Toxicol Appl Pharmacol 1996; 141: 595-606.
38. Becquemont L, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P, Beaune P. Use of heterologously expressed human cytochrome P4501A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 1998; 8: 101-108.
39. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57: 465-480.
40. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochrome P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 1998; 11: 659-665.
41. Facciolá G, Hidestrand M, von Baher C, Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 2001; 56: 881-888.
42. Ching MS, Bichara N, Blake CL, Ghabrial H, Tukey RH, Smallwood RA. Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. Drug Metab Dispos 1996; 24: 692-694.
43. Guengerich FP, Parikh A, Turesky RJ, Josephy PD. Inter-individual differences in the metabolism of environmental toxicants: cytochrome P4501A2 as a prototype. Mutat Res 1999; 428: 115-124.
44. Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996; 26: 395-403.
45. Nunoya K-I, Yokoi Y, Kimura K, Kodama T, Funayama M, Inoue K, Nagashima K, Funae Y, Shimada N, Green C, Kamataki T. (+)-Cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P4502A6 in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 768-774.
46. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282: 1608-1614.
47. Torchin CD, McNeilly PJ, Kapetanovic IM, Strong JM, Kupferberg HJ. Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metab Dispos 1996; 24: 1002-1008.
48. Jones BC, Tyman CA, Smith DA. Identification of the cytochrome P450 isoforms involved in O-demethylation of 4-nitroanisole in human liver microsomes. Xenobiotica 1997; 27: 1025-1037.
49. Nakajima M, Tamamoto T, Nunoya K-I, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24: 1212-1217.
50. Nakajima M, Tamamoto T, Nunoya K-I, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 1010-1015.
51. Chen W, Koenigs LL, Thompson SJ, Peter RM, Rettie AE, Trager WF, Nelson SD. Oxidation of acetamidophen to its toxic quinone imine and nontoxic catechol by Baculovirus-expressed and purified human cytochromes P4502E1 and2A6. Chem Res Toxicol 1998; 11: 295-301.
52. Reigh G, McMahon H, Ishizaki M, Ohara T, Shimane K, Esumi Y, Green C, Tyson C, Ninomiya S-I. Cytochrome P450 species involved in the metabolism of quinoline. Carcinogenesis 1996; 17: 1989-1996.
53. m isoforms. Drug Metab Dispos 1998; 26: 605-607.
54. Liu C, Zhuo X, Gonzalez FJ, Ding X. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: role in metabolic activation of nasal toxicants. Mol Pharmacol 1996; 50: 781-788.
55. Ekins S, Wrighton SA. The role of CYP2B6 in human xenobiotic metabolism, Drug Metab Rev 1999; 31: 719-754.
56. Heyn H, White RC, Stevens JC. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 1996; 24: 948-954.
57. Stevens J, Hauer M, Beck J, Voorman R. Further characterization of human liver CYP2B6 expression and catalytic function. Drug Metab Rev 2000; 32 (Suppl 2): 218.
58. Dehal SS, Kupfer D. Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Drug Metab Dispos 1994; 22: 937-946.
59. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424-432.
60. Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 1999; 58: 1201-1208.
61. Crespi CL, Chang TKH, Waxman DJ. High-performance liquid Chromatographic analysis of CYP2C8-catalyzed paclitaxel 6α-hydroxylation. In: Phillips IR, Shephard EA, eds. Cytochrome P450 Protocols. Totowa, NJ: Humana Press, 1998; 123-127.
62. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbmazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-1979.
63. Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Bretano C, Jaillon P. Cytochrome P4503A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999; 27: 1068-1073.
64. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacokinet 1998; 53: 469-473.
65. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, Wu S. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996; 330: 87-96.
66. Leo MA, Lasker JM, Raucy JL, Kim C-I, Black M, Lieber CS. Metabolism of retinol and retinoic acid by human liver cytochrome P45011C8. Arch Biochem Biophys 1989; 269: 305-312.
67. Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Ha Duong N-T, Battioni P, Dansette PM, Mansuy D. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P4502Cs. Biochemistry 1999; 38: 14264-14270.
68. TB (CYP2C) controls mefenamic acid elimination. Clin Pharmacol Ther 1994; 55: 139.
69. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 CYP2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000; 28: 1303-1310.
70. Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ. Cytochromes P4501A2 and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996; 51: 1003-1008.
71. TB (CYP2C subfamily) in the actions of non-steroidal anti-inflammatory drugs. Drugs Exp Clin Res 1993; 19: 189-195.
72. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24: 1401-1403.
73. Stearns RA, Chakravarty PK, Chen R, Chiu S-H. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Drug Metab Dispos 1995; 23: 207-215.
74. Bonnabry P, Leeman T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam, Eur J Clin Pharmacol 1996; 49: 305-308.
75. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-530.
76. Tsao C-C, Wester MR, Ghanayem B, Coulter SJ, Ghanas B, Johnson EF, Goldstein JA. Identification of human CYP2C19 residues that confer S-mephenytoin 4′-hydroxylase activity to CYP2C9. Biochemistry 2001; 40: 1937-1944.
77. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37: 413-420.
78. McGinnity DF, Griffin SJ, Moody GC, Voice M, Hanlon S, Freidberg T, Riley RJ. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P450 enzymes expressed in Escherichia coli. Drug Metab Dispos 1999; 27: 1017-1023.
79. VandenBranden M, Ring BJ, Binkley SN, Wrighton SA. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996; 6: 81-91.
80. Knodell RG, Dubey RK, Wilkinson GR, Guengerich FP. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 1988; 245: 845-849.
81. Kobayashi K, Kogo M, Tani M, Shimada N, Ishizaki T, Numazawa S, Yoshida T, Yamamoto T, Kuroiwa Y, Chiba K. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes. Drug Metab Dispos 2001; 29: 36-40.
82. Hoskins J, Shenfield G, Murray M, Gross A. Characterization of moclobemide W-oxidation in human liver microsomes. Xenobiotica 2001; 31: 387-397.
83. Koyama E, Chiba K, Tani M, Ishizaki T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 1997; 281: 1199-1210.
84. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes. Drug Metab Dispos 1996; 24: 610-614.
85. Ellis SW, Rowland K, Ackland MJ, Rekka E, Simula AP, Lennard MS, Wolf CR, Tucker GT. Influence of amino acid residue 374 of cytochrome P4502D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochem J 1996; 316: 647-654.
86. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TYY. The demethylation of methylenedioxymethanphetamine ('Ecstasty') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47: 1151-1156.
87. Modi S, Gilham DE, Sutcliffe MJ, Lian L-Y, Primrose WU, Wolf CR, Roberts GCK. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P4502D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 1997; 36: 4461-4470.
88. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 1993; 46: 1975-1981.
89. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P4501IE1. Chem Res Toxicol 1990; 3: 566-573.
90. Iwata H, Fujita K-I, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 1998; 55: 1315-1325.
91. Clarke SE, Baldwin SJ, Bloomer JC, Ayrton AD, Sozio RS, Chenery RJ. Lauric acid as a model substrate for the simultaneous determination of cytochrome P4502E1 and 4A in hepatic microsomes. Chem Res Toxicol 1994; 7: 836-842.
92. Duescher RJ, Elfarra AA. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P4502A6 and 2E1. Arch Biochem Biophys 1994; 311: 342-349.
93. Spracklin DK, Hankins DC, Fisher JM, Thummel KE, Kharasch ED. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther 1997; 281: 400-411.
94. Bell LC, Guengerich FP. Oxidation kinetics of ethanol by human cytochrome P450 2E1. J Biol Chem 1997; 272: 29643-29651.
95. Nedelcheva V, Gut I, Soucek P, Tichavska B, Tynkova L, Mraz J, Guengerich FP, Ingelman-Sundberg M. Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression. Arch Toxicol 1999; 73: 33-40.
96. Zangar RC, Benson JM, Burnett VL, Springer DL. Cytochrome P4502E1 is the primary enzyme responsible for low-dose carbon tetrachloride metabolism in human liver microsomes. Chem-Biol Interact 2000; 125: 233-243.
97. Guengerich FP, Kim D-H, Iwasaki M. Role of human cytochrome P450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168-179.
98. Dupont I, Berthou F, Bodenez P, Bardou L, Guirriec C, Stephan N, Dreano Y, Lucas D. Involvement of cytochromes P450 2E1 and 3A4 in the 5-hydroxylation of salicylate in humans. Drug Metab Dispos 1999; 27: 322-326.
99. Lewis DFV, Dickins M. Substrate SARs in human P450s. Drug Discov Today 2002; 7: 918-925.
100. Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P4502C9: an approach using designed tienilic acid derivatives and molecular modelling. Biochemistry 1995; 34: 10365-10375.